EVALUATION OF THE EFFICACY OF THE ANGIOTENSIN RECEPTOR–NEPRILYSIN INHIBITOR (SACUBITRIL/VALSARTAN) IN PATIENTS WITH CHRONIC HEART FAILURE AND RENAL DYSFUNCTION.
Keywords:
Chronic heart failure, renal dysfunction, cardiorenal syndrome, sacubitril/valsartan, ARNIAbstract
Chronic heart failure (CHF) is frequently accompanied by renal dysfunction, forming cardiorenal syndrome and significantly worsening prognosis. Sacubitril/valsartan, an angiotensin receptor–neprilysin inhibitor (ARNI), has demonstrated superior outcomes compared with conventional renin–angiotensin system blockade; however, data in patients with impaired renal function remain limited. To evaluate the clinical efficacy, cardiac remodeling effects, and renal safety of sacubitril/valsartan in patients with chronic heart failure and renal dysfunction.
Downloads
References
Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017;3(1):7–11.
Roger VL. Epidemiology of heart failure: a contemporary perspective. Circ Res. 2021;128(10):1421–1434.
Damman K, Valente MAE, Voors AA, O’Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure. Eur Heart J. 2014;35(7):455–469.
Smith GL, Lichtman JH, Bracken MB, et al. Renal impairment and outcomes in heart failure. J Am Coll Cardiol. 2006;47(10):1987–1996.
Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52(19):1527–1539.
Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med. 1999;341(8):577–585.
Zannad F, Rossignol P. Cardiorenal syndrome revisited. Circulation. 2018;138(9):929–944.
Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1992;327(10):669–677.
Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor–associated elevations in serum creatinine. Arch Intern Med. 2000;160(5):685–693.
Jhund PS, McMurray JJV. Neprilysin inhibition in heart failure: a clinical perspective. Heart. 2016;102(17):1342–1352.
Volpe M, Rubattu S, Burnett J. Natriuretic peptides in cardiovascular diseases. Eur Heart J. 2018;39(5):386–395.
McMurray JJV, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004.
Wachter R, Senni M, Belohlavek J, et al. Initiation of sacubitril/valsartan in heart failure patients. Eur J Heart Fail. 2019;21(8):998–1007.
Damman K, Gori M, Claggett B, et al. Renal effects and associated outcomes during angiotensin–neprilysin inhibition in heart failure. Circulation. 2018;138(6):542–548.
Silverman DN, Plante TB, Infeld M, et al. Barriers to sacubitril/valsartan use in clinical practice. J Am Heart Assoc. 2020;9(11):e015420.
Solomon SD, Rizkala AR, Gong J, et al. Angiotensin receptor–neprilysin inhibition and ventricular remodeling. JAMA. 2019;322(11):1085–1095.
Desai AS, Solomon SD, Shah AM, et al. Effect of sacubitril/valsartan on renal function. Lancet. 2016;388(10043):475–485.
Voors AA, Gori M, Senni M, et al. Renal effects of neprilysin inhibition in heart failure. Eur J Heart Fail. 2015;17(5):510–517.
Greene SJ, Butler J, Albert NM, et al. Medical therapy for heart failure with reduced ejection fraction in real-world practice. JACC Heart Fail. 2020;8(3):191–201.
Vardeny O, Miller R, Solomon SD. Combined neprilysin and renin–angiotensin system inhibition for heart failure. Am Heart J. 2017;174:55–63.
McDonagh TA, Metra M, Adamo M, et al. 2023 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(4):359–372
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
